I agree; just for reference AMBOSS’s denosumab’s page “In giant cell tumors of bone, stromal cells express RANKL and osteoclast-like giant cells express RANK receptor; signaling through the RANK receptor contributes to osteolysis and tumor growth. Denosumab prevents RANKL from activating the receptor on the surfaces of osteoclasts, their precursors, and osteoclast-like giant cells.” Here’s another non-AMBOSS source: https://www.sciencedirect.com/topics/medicine-and-dentistry/osteoclastoma#:~:text=Multinucleated%20osteoclasts%20that%20form%20giant,-expressing%20tumor%2Fstromal%20cells.